Cara Therapeutics Inc

+0.15 (+1.76%)
4:14:44 PM EDT: $8.80 +0.12 (+1.38%)
Earnings Announcements

Cara Says Q1 Net Loss Was $0.52 Per Basic, Diluted Share

Published: 05/09/2022 21:23 GMT
Cara Therapeutics Inc (CARA) - Cara Therapeutics Reports First Quarter 2022 Financial Results.
Cash, Cash Equivalents and Marketable Securities at March 31, 2022 Totaled $209.6 Million.
For Q1 of 2022, Net Loss Was $0.52 per Basic and Diluted Share.
Cash Runway Into First Half of 2024.
Q1 Earnings per Share View $-0.54 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $21.32 Million
Adjusted EPS is expected to be -$0.26

Next Quarter Revenue Guidance is expected to be $17.64 Million
Next Quarter EPS Guidance is expected to be -$0.36

More details on our Analysts Page.